Newling DW - Search Results

1

Prognostic factors in hormone-resistant progressing cancer of the prostate.

Fosså SD, Dearnaley DP, Law M, Gad J, Newling DW, Tveter K. Fosså SD, et al. Among authors: newling dw. Ann Oncol. 1992 May;3(5):361-6. doi: 10.1093/oxfordjournals.annonc.a058207. Ann Oncol. 1992. PMID: 1616889 Free article.

2

Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group.

Fosså SD, Aaronson NK, Newling D, van Cangh PJ, Denis L, Kurth KH, de Pauw M. Fosså SD, et al. Eur J Cancer. 1990;26(11-12):1133-6. doi: 10.1016/0277-5379(90)90269-y. Eur J Cancer. 1990. PMID: 2149995 Clinical Trial.

3

Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment.

Fosså SD, Paus E, Lindegaard M, Newling DW. Fosså SD, et al. Among authors: newling dw. Br J Urol. 1992 Feb;69(2):175-9. doi: 10.1111/j.1464-410x.1992.tb15491.x. Br J Urol. 1992. PMID: 1371425

4

Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer.

Fosså SD, Aaronson N, Calais da Silva F, Denis L, Newling D, Hosbach G, Kaalhus O. Fosså SD, et al. Eur Urol. 1989;16(5):335-9. doi: 10.1159/000471611. Eur Urol. 1989. PMID: 2476317

5

Assessment of hormone refractory prostate cancer.

Newling D, Fosså SD, Andersson L, Abrahamsson PA, Aso Y, Eisenberger MA, Khoury S, Kozlowski JS, Kelly K, Scher H, Hartley-Asp B. Newling D, et al. Urology. 1997 Apr;49(4A Suppl):46-53. doi: 10.1016/s0090-4295(99)80323-9. Urology. 1997. PMID: 9111614 Free article.

6

Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865).

Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauw M, Sylvester R. Newling DW, et al. J Urol. 1993 Dec;150(6):1840-4. doi: 10.1016/s0022-5347(17)35911-6. J Urol. 1993. PMID: 8230517 Clinical Trial.

7

Defining an international research agenda for quality of life in men with prostate cancer.

Litwin MS, Fitzpatrick JM, Fossa SD, Newling DW. Litwin MS, et al. Among authors: newling dw. Prostate. 1999 Sep 15;41(1):58-67. doi: 10.1002/(sici)1097-0045(19990915)41:1<58::aid-pros8>3.0.co;2-3. Prostate. 1999. PMID: 10440876

8

Comparison of the effects of high dose Estramustine phosphate and mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: an interim analysis of EORTC-GU Group study no. 30865.

Newling DW, Fossa S, Tunn U, Kurth KH, De Pauw M, Sylvester R. Newling DW, et al. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):971-5. doi: 10.1016/0960-0760(90)90452-q. J Steroid Biochem Mol Biol. 1990. PMID: 2126739 Clinical Trial.

9

Vincristine in advanced bladder cancer: a European organization for research on treatment of cancer (EORTC) phase II study.

Richards B, Newling D, Fossa S, Bastable JR, Denis L, Jones WB, de Pauw M. Richards B, et al. Cancer Treat Rep. 1983 Jun;67(6):575-7. Cancer Treat Rep. 1983. PMID: 6861163

10

Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.

Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K, Cockshott ID. Tyrrell CJ, et al. Eur Urol. 1998;33(1):39-53. doi: 10.1159/000019526. Eur Urol. 1998. PMID: 9471040 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

140 results

Search Page

Filters